G Medical Innovations Holdings Ltd. Sets Date to Announce Half Year Results for the Six Months Ended June 30, 2021
G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) announced plans to release its half-year financial results for the period ending June 30, 2021, on September 15, 2021. The company specializes in telehealth, medical devices, and remote patient monitoring, focusing on next-generation mHealth solutions. Their key products include the Prizma medical device and the Extended Holter Patch System, aimed at enhancing health monitoring for patients with cardiovascular and pulmonary diseases. For more details, visit gmedinnovations.com.
- G Medical Innovations is advancing in the telehealth sector with innovative products.
- The Prizma device allows comprehensive monitoring through smartphones.
- Concerns may arise regarding the company's ability to deliver continuous growth.
- -
TEL AVIV and NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announcedplans to release its half year financial results for the six months ended June 30, 2021 prior to the open of regular stock market trading hours on Wednesday, September 15, 2021.
About G Medical Innovations Holdings Ltd.
G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. For more information, please visit https://gmedinnovations.com/
Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including with respect to the possible offering of additional units, and the intended use of proceeds. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
G Medical Innovations Holdings Ltd. Company Contact
Investor Relations
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
FAQ
When will G Medical Innovations Holdings Ltd. release its financial results?
What are the main products of G Medical Innovations Holdings Ltd.?
What is the focus of G Medical Innovations Holdings Ltd.?
What date is significant for G Medical Innovations Holdings Ltd. in September 2021?
What is the stock symbol for G Medical Innovations Holdings Ltd.?
